📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-07 18:08
112 analysed today
FollowTelegram
112
Today
149,513
All-time analysed
42,888
Positive
6,650
Negative
91,302
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Net Profit Rises to ₹0.54 Cr; Consolidated Revenue Up 29.6% YoY to ₹37.71 Cr
Indrayani Biotech reported consolidated revenue from operations of ₹37.71 crore for Q1 FY27 (ended June 30, 2026), up 29.6% YoY from ₹29.10 crore in Q1 FY26. Consolidated net profit reached ₹0.54 crore compared to ₹0.16 crore in the same period last year. On a standalone basis, revenue fell 37.9% YoY to ₹4.15 crore, while standalone net profit came in at ₹0.15 crore. The company also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
Confidence: HIGH
What changedIndrayani Biotech declared its unaudited standalone and consolidated Q1 FY27 financial results and reconstituted key board committees.
Why it mattersDemonstrates operating turnaround and profit expansion on a consolidated level, although standalone performance saw a significant revenue drop.
Consolidated Revenue (Q1): ₹3,770.55 lakhsConsolidated PAT (Q1): ₹54.00 lakhsStandalone Revenue (Q1): ₹415.34 lakhsStandalone PAT (Q1): ₹14.50 lakhsConsolidated Diluted EPS: ₹0.06
📅 Short termConsolidated profit recovery may support market sentiment, offset somewhat by delayed reporting for the June 2026 quarter in October 2026.
📈 Long termSustained execution across subsidiaries like Dindigul Farm Product Limited remains crucial for maintaining group profitability and managing debt levels.
⚠ Risk flags
- Divergence between standalone and consolidated performance indicates heavy dependency on subsidiaries
- Delayed filing timeline (Q1 FY27 filed in October 2026)
Key Highlights
Consolidated revenue from operations increased 29.6% YoY to ₹3,770.55 lakhs (₹37.71 crore)
Consolidated profit after tax stood at ₹54.00 lakhs compared to ₹15.65 lakhs in Q1 FY26
Profit attributable to owners of the company reported at ₹26.22 lakhs with basic EPS of ₹0.06
Standalone revenue from operations dropped YoY to ₹415.34 lakhs from ₹668.57 lakhs
Board approved reconstitution of Audit, Stakeholder Relationship, and Rights Issue Committees
👀 What to Watch
Track subsequent quarterly filings to see if top-line growth sustains at the consolidated level and monitor developments regarding the Rights Issue Committee.
Q1 FY27 Net Profit Rises to ₹0.54 Cr; Consolidated Revenue Up 29.6% YoY to ₹37.71 Cr
Indrayani Biotech reported consolidated revenue from operations of ₹37.71 crore for Q1 FY27 (ended June 30, 2026), up 29.6% YoY from ₹29.10 crore in Q1 FY26. Consolidated net profit reached ₹0.54 crore compared to ₹0.16 crore in the same period last year. On a standalone basis, revenue fell 37.9% YoY to ₹4.15 crore, while standalone net profit came in at ₹0.15 crore. The company also reconstituted its Audit, Stakeholder Relationship, and Rights Issue Committees.
Confidence: HIGH
What changedIndrayani Biotech declared its unaudited standalone and consolidated Q1 FY27 financial results and reconstituted key board committees.
Why it mattersDemonstrates operating turnaround and profit expansion on a consolidated level, although standalone performance saw a significant revenue drop.
Consolidated Revenue (Q1): ₹3,770.55 lakhsConsolidated PAT (Q1): ₹54.00 lakhsStandalone Revenue (Q1): ₹415.34 lakhsStandalone PAT (Q1): ₹14.50 lakhsConsolidated Diluted EPS: ₹0.06
📅 Short termConsolidated profit recovery may support market sentiment, offset somewhat by delayed reporting for the June 2026 quarter in October 2026.
📈 Long termSustained execution across subsidiaries like Dindigul Farm Product Limited remains crucial for maintaining group profitability and managing debt levels.
⚠ Risk flags
- Divergence between standalone and consolidated performance indicates heavy dependency on subsidiaries
- Delayed filing timeline (Q1 FY27 filed in October 2026)
Key Highlights
Consolidated revenue from operations increased 29.6% YoY to ₹3,770.55 lakhs (₹37.71 crore)
Consolidated profit after tax stood at ₹54.00 lakhs compared to ₹15.65 lakhs in Q1 FY26
Profit attributable to owners of the company reported at ₹26.22 lakhs with basic EPS of ₹0.06
Standalone revenue from operations dropped YoY to ₹415.34 lakhs from ₹668.57 lakhs
Board approved reconstitution of Audit, Stakeholder Relationship, and Rights Issue Committees
👀 What to Watch
Track subsequent quarterly filings to see if top-line growth sustains at the consolidated level and monitor developments regarding the Rights Issue Committee.
Indrayani Biotech Sells 1.83% Stake in Subsidiary Dindigul Farm via Open Market
Indrayani Biotech Limited has completed the sale of a 1.83% stake in its subsidiary, Dindigul Farm Product Limited, via the open market on September 30, 2026. Following this divestment, the company's holding in Dindigul Farm Product stands reduced to 27.05%. The subsidiary is a significant contributor to the group, generating Rs 90.04 Cr in turnover, which accounts for 65.33% of consolidated revenues. The exact sale proceeds and consideration amount were not quantified in the filing.
Confidence: HIGH
What changedIndrayani Biotech lowered its equity holding in subsidiary Dindigul Farm Product Limited from 28.88% to 27.05% through an open-market sale.
Why it mattersDindigul Farm Product accounts for 65.33% of the company's revenue profile; gradual trimming of ownership may eventually impact consolidated financial reporting and balance sheet scale.
Stake divested: 1.83%Post-sale stake: 27.05%Subsidiary turnover: Rs.900,432,000Subsidiary revenue contribution: 65.33%Total consideration received: not disclosed
📅 Short termNeutral market impact expected as the stake sale of 1.83% is relatively small, although the realized cash inflow will be monitored.
📈 Long termAs Indrayani Biotech's holding declines closer to non-controlling levels, changes to consolidated financials or accounting treatment of Dindigul Farm Product remain a key watchpoint.
⚠ Risk flags
- Lack of disclosure on exact sale consideration received
- Dilution in a core subsidiary contributing over 65% of group revenue
Key Highlights
Divested 1.83% shareholding/control in subsidiary Dindigul Farm Product Limited
Post-disposal shareholding drops to 27.05%
Dindigul Farm Product contributed turnover of Rs 90.04 Cr (65.33% of net worth/revenue) during the last financial year
Transaction executed through open market sales with completion on September 30, 2026
👀 What to Watch
Track subsequent quarterly filings to identify the total consideration received and monitor whether further dilution will lead to deconsolidation of Dindigul Farm Product.
Indrayani Biotech FY26 Standalone Revenue Drops 42% to ₹21.90 Cr; Auditor Issues Qualified Opinion
Indrayani Biotech reported audited standalone revenue of ₹21.90 Cr (₹2,189.78 Lakhs) for FY26, down 42% YoY from ₹37.77 Cr in FY25. Standalone net profit declined 51.6% YoY to ₹0.70 Cr (₹69.97 Lakhs) with EPS dropping to ₹0.15 from ₹0.32 in FY25. Statutory auditors issued a qualified opinion on the consolidated results due to non-Ind AS accounting at two subsidiaries and unconfirmed balances in loans, receivables, and payables. Additionally, standalone cash flow from operations worsened sharply to negative ₹14.10 Cr in FY26.
Confidence: HIGH
What changedIndrayani Biotech published audited FY26 results showing a sharp standalone top-line and bottom-line contraction alongside consolidated audit qualifications.
Why it mattersA 42% decline in standalone revenues coupled with audit qualifications across multiple subsidiaries highlights financial performance pressure and internal reporting vulnerabilities.
Standalone FY26 Revenue: ₹2,189.78 LakhsStandalone FY26 PAT: ₹69.97 LakhsStandalone FY26 EPS: ₹0.15Unconfirmed Creditors (HSL Prime): ₹61,82,938Standalone Operating Cash Flow: -₹1,410.28 Lakhs
📅 Short termSubdued financial performance and auditor qualifications are likely to dampen near-term stock sentiment.
📈 Long termRecovery depends on transition of subsidiaries to Ind AS compliance, resolving reconciliation discrepancies, and reviving operating cash flows.
⚠ Risk flags
- Auditor qualified opinion on consolidated accounts
- Non-Ind AS reporting at two subsidiaries
- Negative standalone operating cash flow of ₹14.10 Cr
- Unconfirmed trade balances and loans
Key Highlights
Standalone FY26 revenue from operations declined 42% YoY to ₹2,189.78 Lakhs from ₹3,776.91 Lakhs in FY25.
Standalone net profit fell 51.6% YoY to ₹69.97 Lakhs, leading to an EPS of ₹0.15 compared to ₹0.32 in the previous year.
Statutory auditors gave a qualified opinion on consolidated results citing Matrix Boilers and Kniss Laboratories reporting under Indian GAAP instead of Ind AS.
Auditor flagged unconfirmed trade creditors of ₹61.83 Lakhs (41% of total liabilities) in subsidiary HSL Prime Properties.
Net cash flow from operating activities on a standalone basis deteriorated to -₹1,410.28 Lakhs in FY26 from +₹1,735.34 Lakhs in FY25.
👀 What to Watch
Track upcoming quarterly updates to see if the audit qualifications regarding subsidiary accounting standards and balance reconciliations are addressed by management.
Indrayani Biotech Reports FY26 Results; Auditors Issue Qualified Opinion on Multiple Counts
Indrayani Biotech approved its audited consolidated financial results for the quarter and year ended March 31, 2026. For FY26, consolidated revenue stood at Rs 172.84 Cr with a net profit of Rs 2.27 Cr, recovering from a loss of Rs 6.0 Cr in FY25. However, statutory auditors issued a qualified opinion citing Indian GAAP compliance instead of Ind AS for two subsidiaries and unconfirmed balances across loans, receivables, and trade creditors.
Confidence: HIGH
What changedThe Board approved audited full-year FY26 results with statutory auditor qualification remarks.
Why it mattersWhile FY26 marked a return to profitability (Rs 2.27 Cr PAT), auditor qualifications regarding accounting standards and unverified balances pose governance and reporting risks.
Unconfirmed Trade Creditors (HSL Prime): Rs. 61,82,938Other Auditor Covered Assets: ₹17,128.01 lakhsOther Auditor Covered Revenues: ₹11,335.73 lakhsManagement Certified Subsidiary Assets: ₹311.43 lakhs
📅 Short termNegative sentiment expected due to audit qualifications and reporting delays.
📈 Long termCredibility depends on standardizing accounting frameworks across subsidiaries and tightening internal financial controls.
⚠ Risk flags
- Auditor qualified opinion on Ind AS non-compliance in two subsidiaries
- Unconfirmed balances in trade receivables, loans, and creditors
- High debt-to-equity ratio of 1.06x
Key Highlights
Auditors issued a qualified opinion as two subsidiaries (Matrix Boilers and Kniss Laboratories) prepared financials under Indian GAAP instead of Ind AS.
Unconfirmed and unreconciled balances flagged across loans, other current assets, and trade receivables.
Subsidiary HSL Prime Properties lacked balance confirmations for trade creditors worth Rs 61,82,938 (~41% of its liabilities).
Other auditors covered subsidiaries accounting for ₹11,335.73 lakhs (₹113.36 Cr) in revenue and ₹17,128.01 lakhs in assets.
👀 What to Watch
Monitor subsequent quarterly filings to see if management resolves Ind AS conversion issues for subsidiaries and reconciles unconfirmed balances.
Indrayani Biotech Approves Delayed FY26 Results; Auditors Issue Qualified Opinion
Indrayani Biotech approved its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, on August 17, 2026. Statutory auditors issued a Qualified Opinion citing unconfirmed balances in loans, other current assets, and trade receivables. Furthermore, two subsidiaries compiled statements under Indian GAAP rather than Ind AS, and another subsidiary lacked confirmation for Rs 61.83 lakh in trade creditors (41% of its liabilities). Other auditors audited entities contributing ₹113.36 Cr in revenue.
Confidence: HIGH
What changedThe board approved delayed FY26 audited results accompanied by a qualified audit report flagging reporting and reconciliation gaps.
Why it mattersAudit qualifications and delayed filings raise corporate governance and financial reporting risks, creating uncertainty around true consolidated asset and earnings quality.
Unconfirmed trade creditors (HSL Prime): Rs 61,82,938Other-audited subsidiary assets: ₹17,128.01 lakhsOther-audited subsidiary revenue: ₹11,335.73 lakhsManagement-certified subsidiary revenue: ₹448.85 lakhs
📅 Short termNegative sentiment likely due to the delayed submission and multiple audit qualifications regarding accounting standards and balance verifications.
📈 Long termPersistent reporting weaknesses and lack of accounting uniformity across subsidiaries may keep valuation multiples depressed.
⚠ Risk flags
- Auditor qualification on loans, trade receivables, and other current assets
- Non-compliance with Ind AS in two subsidiaries
- Unconfirmed creditor balances representing 41% of a subsidiary's liabilities
Key Highlights
Auditors issued a Qualified Opinion on FY26 consolidated financial statements due to balance reconciliation and Ind AS non-compliance issues.
Subsidiaries Matrix Boilers and Kniss Laboratories compiled accounts under Indian GAAP instead of Ind AS, with unascertainable P&L impact.
Subsidiary HSL Prime Properties had unconfirmed trade creditors of Rs 61,82,938 (~41% of its total liabilities).
Entities audited by other auditors contributed ₹17,128.01 lakhs in assets and ₹11,335.73 lakhs in revenues.
👀 What to Watch
Monitor future disclosures to assess if management resolves balance reconciliations and transitions all operating subsidiaries to Ind AS compliance.
